Triiodothyronine

What do your blood test results mean? A toxicologist explains the basics of how to interpret them

Retrieved on: 
Tuesday, February 6, 2024
Glycated hemoglobin, Thyroid, BMP, Physical examination, Disorder, Hypothyroidism, Cell, BUN, Immune system, History, RBC, Heart, Blood urea nitrogen, Diabetes, Biomarker, Blood, Patient, Kidney, Triiodothyronine, Temperature, HB, TSH, Anemia, Nutrient, A1C, Disease, Thyroid hormones, Brain, Hematocrit, Fatigue, Waste, Health, HCT, Hormone, Plasma, Woman, Medical imaging

As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.

Key Points: 
  • As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.
  • Understanding what common blood tests are intended to measure can help you better interpret the results.
  • If you have results from a recent blood test handy, please follow along.

Normal blood test ranges

  • This range is essentially the upper and lower limits within which most healthy people’s test results are expected to fall.
  • To determine how your test results compare with the normal range, you need to check the reference interval listed on your lab report.
  • If you have results for a given test from different labs, your clinician will likely focus on test trends relative to their reference intervals and not the numerical results themselves.

Interpreting your blood test results

  • There are numerous blood panels intended to test specific aspects of your health.
  • These include panels that look at the cellular components of your blood, biomarkers of kidney and liver function, and many more.
  • This results from either lower than normal levels of red blood cells or a decrease in the quantity or quality of hemoglobin, the protein that allows these cells to transport oxygen.
  • A complete blood count panel measures various components of the blood to provide a comprehensive overview of the cells that make it up.
  • Low values of red blood cell count, or RBC, hemoglobin, or Hb, and hematocrit, or HCT, would indicate that the patient is suffering from anemia.
  • Providing additional information is the basic metabolic panel, or BMP, which measures the amount various substances in your blood.


With results from each of these panels, the health professional would assess the patient’s values relative to their reference intervals and determine which condition they most likely have. Understanding the purpose of blood tests and how to interpret them can help patients partner with their health care providers and become more informed about their health.
Brad Reisfeld does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting

Retrieved on: 
Friday, September 29, 2023
Thyroid hormones, TSH, American Thyroid Association, Histology, Depression, FSE, ATA, FT4, Quality of life, PSH, Hypothyroidism, Weight gain, Thyroidectomy, Triiodothyronine, Patient, Cell, Annual general meeting, TSX, Poster, Memory, Fatigue, Thyroid, Medical imaging, Pharmaceutical industry

Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.

Key Points: 
  • Thyroid stimulating hormone (TSH) levels had a significant peak immediately after thyroidectomy, with a gradual decline observed starting five weeks after the re-implantation of thyroid glands.
  • Newly reported radio-isotope uptake imaging and histology assessments confirmed the presence of healthy and functional thyroid tissues within the Cell Pouch six months following re-implantation.
  • “With Sernova’s Cell Pouch System, we aim to improve quality of life with a treatment for post-operative hypothyroidism.
  • These new data replicate a human clinical scenario in which thyroid tissue is reimplanted into the patient, via the Cell Pouch, leading to the restoration of normal thyroid function.

Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Retrieved on: 
Monday, January 30, 2023
Cell, PLOS One, Weight gain, ST, Triiodothyronine, MD, Thyroid, Constipation, North Central Cancer Treatment Group, Synthetic control method, PMID, Amnesia, TSX, Thyroid hormones, JAMA Otolaryngology–Head & Neck Surgery, Survival, FACS, PSH, Bachelor of Science, Depression, FRCSC, University, Institute for Quality and Efficiency in Health Care, Patient, The Control Group, Hypothyroidism, FSE, Faculty, Thyroidectomy, Medical school, Quality, Haemophilia, Control Group, Metabolism, Dentistry, Pharmaceutical industry, Medicine, T4

The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.

Key Points: 
  • The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.
  • The thyroid gland of each Treatment Group subject was removed, prepared with minimal manipulation, and transplanted into the pre-implanted Cell Pouch.
  • Following thyroidectomy in the Treatment Group, the T3 and T4 levels fell initially but subsequently recovered to normal or near-normal levels following thyroid transplant into the Cell Pouch.
  • Control Group subjects received the Cell Pouch implant and underwent total thyroidectomy but did not receive a thyroid transplant.

EQS-News: Sernova Announces Advancements with its Novel Cell Pouch System(TM) to Preserve Thyroid Function Following Total Thyroidectomy

Retrieved on: 
Thursday, February 2, 2023
Constipation, Institute for Quality and Efficiency in Health Care, Thyroid, ST, University, Thyroidectomy, Amnesia, Quality, Medical school, Bachelor of Science, Haemophilia, FSE, Depression, TSX, MD, FRCSC, PMID, Control Group, Weight gain, Survival, PLOS One, Metabolism, Patient, Hypothyroidism, JAMA Otolaryngology–Head & Neck Surgery, North Central Cancer Treatment Group, FACS, Triiodothyronine, Faculty, The Control Group, Thyroid hormones, Synthetic control method, PSH, Cell, Dentistry, Pharmaceutical industry, Medicine, T4

The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.

Key Points: 
  • The study was conducted in a pre-clinical animal model whereby the Cell Pouch was pre-implanted for several weeks prior to each subject undergoing total thyroidectomy.
  • The thyroid gland of each Treatment Group subject was removed, prepared with minimal manipulation, and transplanted into the pre-implanted Cell Pouch.
  • Following thyroidectomy in the Treatment Group, the T3 and T4 levels fell initially but subsequently recovered to normal or near-normal levels following thyroid transplant into the Cell Pouch.
  • Control Group subjects received the Cell Pouch implant and underwent total thyroidectomy but did not receive a thyroid transplant.

Global Iodine Market Report 2022 to 2027 - Featuring Algorta Norte, Eskay Iodine, Iofina and Nippoh Chemicals Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 17, 2022
Chemicals, Plastics, Manufacturing, Dairy, Alkylation, Egg, Breast, Iodised salt, Seaweed, Seafood, Intellectual, Goitre, Vegetable, Metabolism, Bandage, Protein, Growth, Hypothyroidism, COVID-19, Triiodothyronine, CT, Compound, Salt, I2, Iodine

These insights are included in the report as a major market contributor.

Key Points: 
  • These insights are included in the report as a major market contributor.
  • Iodine (I2) is a trace element naturally found in dairy products, seafood, seaweed, eggs, and vegetables.
  • This report provides an analysis of the key trends in each sub-segment of the global iodine market, along with forecasts at the global, regional and country level from 2022-2027.
  • The report has categorized the market based on source, form and application.

Global Endocrine Testing Market Analysis/Research Report 2022-2027: Tests to Measure Thyroid-Stimulating Hormone (TSH) are Expected to Influence Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 28, 2022
Health, Biotechnology, First Nations in Ontario, Triiodothyronine, Androgen deficiency, FT4, Thyroid disease, COVID-19, Roche, University Medical Center Groningen, Thyroid, Department, Geriatrics, ATA, American Thyroid Association, FT3, Incidence, Patient, UN, Tobacco, Growth, Risk, Laboratory, Abbott Laboratories, TT3, Growth hormone, Woman, Smoking, Groningen, CAGR, United Nations, Technology, Serum, Research, University of Groningen, Nephrology, Hypothyroidism, TSH, Menopause, University, Hyperthyroidism, Government, Disease, Endocrine system, Man, Medical device, Vaccine, Pharmaceutical industry, Agriculture

Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Key Points: 
  • Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.
  • Since endocrine testing tools are in high demand, market players are more committed to developing new products.
  • The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.
  • As a result, the rise in TSH testing is expected to boost market growth for the global endocrine testing market.

Xeris Pharmaceuticals Completes Enrollment of Its Phase 1 Study of Levothyroxine (XP-8121)

Retrieved on: 
Wednesday, September 1, 2021
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Industry, Company, Medicine, TSH, Thyroid, Twitter, Adherence (medicine), Quality of life, Instagram, U.S. Securities and Exchange Commission, Cmax, Technology, Acquisition, Trial of the century, Pharmacokinetics, SEC, Medical Affairs Bureau, Hormone, Science, Nasdaq, Private Securities Litigation Reform Act, Risk, Absorption, Metabolism, Biostatistics, Regulation, Regulation Fair Disclosure, Safety, Food, Partnership, Patient, Hypothyroidism, Solution, Caregiver, Disclosure, LinkedIn, Triiodothyronine, Plasma, COVID-19, View, Kinetics, Pharmaceutical industry, Generic drug, Medical imaging, Levothyroxine and Hypothyroidism, Xeris Pharmaceuticals, Inc., Celerion, LEVOTHYROXINE AND HYPOTHYROIDISM, XERIS PHARMACEUTICALS, INC., CELERION

The Phase 1 clinical study of levothyroxine (XP-8121) is a single ascending dose crossover design in 30 healthy participants to compare matching doses of oral levothyroxine (Synthroid) and subcutaneous (SC) XP-8121.

Key Points: 
  • The Phase 1 clinical study of levothyroxine (XP-8121) is a single ascending dose crossover design in 30 healthy participants to compare matching doses of oral levothyroxine (Synthroid) and subcutaneous (SC) XP-8121.
  • The primary endpoints of the study are to characterize the absorption and elimination kinetics of XP-8121 and compare bioavailability of XP-8121 to oral levothyroxine.
  • The study is being conducted in partnership with Dr. Danielle Armas and Celerion, a leading contract research organization with extensive experience performing first-in-human studies.
  • The potential for a once weekly subcutaneous injection of levothyroxine would represent a promising novel approach in treating patients with hypothyroidism.

Xeris Pharmaceuticals Announces FDA Acceptance of its IND Application for XeriSol™ Levothyroxine (XP-8121) for the Treatment of Hypothyroidism

Retrieved on: 
Wednesday, August 11, 2021
FDA, Pharmaceutical, Health, Clinical Trials, Acquisition, Thyroid, CEO, Patient, Doctor of Pharmacy, Pharmacokinetics, SEC, Risk, Medical Affairs Bureau, Caregiver, Food, COVID-19, Regulation Fair Disclosure, Compliance, FDA, Triiodothyronine, TSH, Nasdaq, Company, Private Securities Litigation Reform Act, Quality of life, Disclosure, Instagram, Safety, Hypothyroidism, Hormone, Regulation, U.S. Securities and Exchange Commission, Solution, Technology, Food and Drug Administration Amendments Act of 2007, View, IND, LinkedIn, Twitter, Pharmaceutical industry, Levothyroxine and Hypothyroidism, Xeris Pharmaceuticals, Inc., LEVOTHYROXINE AND HYPOTHYROIDISM, XERIS PHARMACEUTICALS, INC.

The active IND enables Xeris to initiate a Phase 1 clinical study for XP-8121 using its novel formulation of levothyroxine in a subcutaneous injection for the treatment of hypothyroidism.

Key Points: 
  • The active IND enables Xeris to initiate a Phase 1 clinical study for XP-8121 using its novel formulation of levothyroxine in a subcutaneous injection for the treatment of hypothyroidism.
  • We believe that a potentially weekly subcutaneous injection of XeriSol levothyroxine can mitigate many of these challenges and improve compliance.
  • The FDA acceptance of our XP-8121 further underscores the applicability of our XeriSol technology and progress of our pipeline.
  • The treatment of choice for correction of hypothyroidism is levothyroxine, which is the mainstay of thyroid hormone replacement therapy.

Global Thyroid Function Tests Market Analysis and Forecast Model 2018: Annualized Total Market Revenue by Segment and Market Outlooks 2015-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 16, 2019
Health, Other Health, Glands, Endocrine system, Thyroid, Blood tests, Chemical pathology, Thyroid function tests, Triiodothyronine, Hypothalamic–pituitary–thyroid axis

The "Thyroid Function Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thyroid Function Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Other TFTs covered in this market model include total T4 tests, free Triiodothyronine (T3) tests, and total T3 tests.
  • Annualized total Thyroid Function Tests market revenue by segment and market outlooks from 2015-2028.
  • Track device sales in the global and country-specific Thyroid Function Tests market from 2015-2028.